View Older Stories View More Recent Stories
-
ROSEN, SKILLED INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AZN
-
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca
-
ROSEN, LEADING INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AZN
-
ROSEN, A TOP-RANKED LAW FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AZN
-
ROSEN, SKILLED INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AZN
-
ROSEN, LEADING INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AZN
-
ROSEN, A TOP-RANKED LAW FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AZN
-
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AZN
-
ROSEN, LEADING INVESTOR COUNSEL Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AZN
-
AZN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AZN
-
Achilles Therapeutics (ACHL) Sells Technology Assets to AstraZeneca (AZN)
-
AstraZeneca (AZN) reports Datopotamab deruxtecan application in the EU for patients with advanced nonsquamous non-small cell lung cancer voluntarily withdrawn
-
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AZN
-
AstraZeneca (AZN) call put ratio 1 call to 1.7 puts as share price up 1.5%
-
AstraZeneca's (AZN) Tagrisso approved in the EU for patients with unresectable EGFR-mutated lung cancer
-
ROSEN, A LEADING LAW FIRM, Encourages AstraZeneca PLC Investors to Inquire About Securities Class Action Investigation - AZN
-
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Inquire About Securities Class Action Investigation - AZN
-
ROSEN, LEADING INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Inquire About Securities Class Action Investigation - AZN
-
Tracer Biotechnologies Announces Agreement with AstraZeneca (AZN) for Next-Generation Cancer Monitoring for Drug Development
-
Truist: 'Potential Impact of Trump's Nominees on Biopharma'
-
AstraZeneca's (AZN) Imfinzi granted Priority Review in the US for patients with muscle-invasive bladder cancer
-
AstraZeneca (AZN): IMFINZI approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
-
AstraZeneca (AZN) Imfinzi approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
-
AstraZeneca (AZN) Appoints Iskra Reic as EVP, International
-
AstraZeneca (AZN) Reports TRUQAP combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic
-
UBS Upgrades AstraZeneca (AZN:LN) (AZN) to Neutral
-
AstraZeneca (AZN) PT Raised to $87 at Leerink Partners
-
AstraZeneca (AZN) call put ratio 1 call to 4.6 puts into quarter results
-
AstraZeneca (AZN) PT Lowered to $88 at BMO Capital
-
AstraZeneca (AZN) Tops Q3 EPS by $1.06
-
AstraZeneca (AZN) invests $3.5B in R&D and manufacturing in the US
-
AstraZeneca (AZN) reports TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial
-
Deutsche Bank Upgrades AstraZeneca (AZN:LN) (AZN) to Hold
-
TD Cowen Reiterates Buy Rating on AstraZeneca (AZN)
-
AstraZeneca (AZN) China President Leon Wang Said To Be Still Detained - Bloomberg
-
AstraZeneca (AZN) comments on share price movements
-
AstraZeneca (AZN) Insurance Fraud Involves Dozens of Senior Executives in China - Report
-
AstraZeneca (AZN) China President currently under investigation
-
AstraZeneca (AZN) reports Enhertu approved in China as first HER2-directed therapy for patients with HER2-mutant metastatic non-small cell lung cancer
-
TD Cowen Reiterates Buy Rating on AstraZeneca (AZN)
-
AstraZeneca (AZN): AIRSUPRA demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma
-
AstraZeneca (AZN) reports Airsupra demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthm
-
AstraZeneca (AZN) entres license agreement for a pre-clinical novel lipid-lowering therapy
-
AstraZeneca (AZN): CALQUENCE granted Priority Review in the US for patients with untreated mantle cell lymphoma
-
AstraZeneca (AZN) reports Calquence granted Priority Review in the US for patients with untreated mantle cell lymphoma
-
Arcus Biosciences (RCUS) Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma
-
AstraZeneca (AZN): ENHERTU granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer
-
AstraZeneca's (AZN) ENHERTU Granted Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer
-
Erste Group Downgrades AstraZeneca (AZN) to Hold
